BioCentury | Aug 8, 2018
Distillery Therapeutics

Cancer

...INDICATION: Pancreatic cancer Patient sample, cell culture and mouse studies suggest inhibiting HNF1A could help treat...
...help treat pancreatic ductal adenocarcinoma (PDAC). In PDAC patient samples, high tumor expression of a HNF1A-induced...
...a non-specific shRNA. Ongoing work includes identifying the roles of HNF1A-regulated genes in PDAC. TARGET/MARKER/PATHWAY: HNF1 homeobox A (HNF1A)...
BioCentury | Jun 16, 2016
Distillery Therapeutics

Therapeutics: Forkhead box A1 (FOXA1); FOXA2; FOXA3; GATA binding protein 4 (GATA4); HNF1 homeobox A (HNF1A); hepatocyte nuclear factor 4 α (HNF4A; TCF) FOXA3,

...adeno-associated virus serotype 6 (AAV6) vectors encoding FOXA1 , FOXA2 , FOXA3 , GATA4 , HNF1A...
...p75 neurotrophin receptor ( p75 NTR )-tagged adenoviral vector serotype 5 (Ad5) encoding FOXA3, GATA4, HNF1A...
...efficiency. TARGET/MARKER/PATHWAY: Forkhead box A1 (FOXA1) ; FOXA2; FOXA3; GATA binding protein 4 (GATA4) ; HNF1 homeobox A (HNF1A)...
BioCentury | Mar 20, 2014
Cover Story

A liver divided

...directly into hepatocytes by transducing them with lentiviruses carrying three genes: HNF1 homeobox A ( HNF1A...
...Shi and Shichun Lu introduced lentiviruses expressing a set of three hepatocyte fate conversion factors- HNF1A...
BioCentury | Aug 15, 2013
Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Direct reprogramming of fibroblasts into induced hepatic stem cells (iHSCs) for liver regeneration iHSCs derived directly from fibroblasts could help treat liver diseases. In culture,...
BioCentury | Apr 11, 2013
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer HNF1 homeobox B (HNF1B) Patient studies suggest genetic and epigenetic variation in HNF1B could be useful for the classification...
BioCentury | Feb 28, 2013
Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes; obesity HNF1 homeobox B (HNF1B); microRNA-802 (miR-802) Mouse and human studies suggest inhibiting miR-802 or increasing HNF1B signaling could help treat obesity and...
BioCentury | Dec 15, 2011
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Liver cancer Hepatocyte nuclear factor 4a (HNF4A; TCF); microRNA-124 (miR-124) Mouse and patient sample studies suggest increasing signaling in the HNF4A-miR-124 pathway could help treat...
BioCentury | Jan 6, 2011
Distillery Techniques

Technology: Assays & screens

Approach Summary Licensing status Publication and contact information Assays & screens Patient-derived cell lines as an in vitro model for drug screening for genetically complex diseases Screening small molecules in patient-derived cell lines could help...
BioCentury | Jan 6, 2011
Tools & Techniques

Modeling genetic complexity in vitro

Harvard researchers believe they have developed a method for generating in vitro models of highly complex genetic diseases, which are difficult to model with standard genetic knockout techniques. 1 With proof of principle in a...
BioCentury | Dec 10, 2009
Distillery Therapeutics

Indication: Gastrointestinal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Gastrointestinal disease Colitis Cadherin 1, type 1, E-cadherin (CDH1); cadherin 3, type 1, P-cadherin (CDH3); hepatocyte nuclear factor 4a (HNFA); laminin b1 (LAMB1) Genomewide association studies...
Items per page:
1 - 10 of 14